Posts by: Alberto Molano

News

Lung Therapeutics announced that it has raised $36 million in Series C financing to fund two projects, including a healthy volunteer Phase 1 clinical trial testing LTI-03, an experimental ... Read more

May 20, 2019May 20, 2019

Exhalative Breath Biomarkers Not Useful to Distinguish Among Different ILDs, Study Reports

News

Measuring three specific biomarkers — nitric oxide, PGE2, and 8‐isoprostane — in the exhaled breath condensates (EBC) or bronchoalveolar lavage fluids (BALF) of patients with different forms of interstitial ... Read more

May 3, 2019May 3, 2019

AstraZeneca Turns to Artificial Intelligence to Speed Discovery of New Medicines for IPF

News

A long-term collaboration was announced to accelerate the discovery of new medicines for idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD) by combining BenevolentAI’s expertise in artificial intelligence ... Read more

February 26, 2019March 5, 2019

Algernon Plans to Test Its Lead Anti-fibrotic Compound in Animal Study of IPF

News

Algernon Pharmaceuticals announced its plans to conduct a new in vivo animal study comparing its lead anti-fibrotic NP-251 compound with clinically relevant doses of both Esbriet (pirfenidone) and Ofev (nintedanib), two approved medicines for the treatment ... Read more

October 31, 2018October 31, 2018

Lung Cancer Has High Incidence, Worse Prognosis Among IPF Patients, Study Finds

News

The incidence of lung cancer is greater among patients with idiopathic pulmonary fibrosis (IPF), compared with the general population, and is associated with a worse prognosis, a new U.S. study ... Read more

Posts by: Alberto Molano

Alberto Molano

Funding Secured for Phase 1 Trial of Potential IPF Treatment LTI-03

Exhalative Breath Biomarkers Not Useful to Distinguish Among Different ILDs, Study Reports

AstraZeneca Turns to Artificial Intelligence to Speed Discovery of New Medicines for IPF

Algernon Plans to Test Its Lead Anti-fibrotic Compound in Animal Study of IPF

Lung Cancer Has High Incidence, Worse Prognosis Among IPF Patients, Study Finds

Pin It on Pinterest